Apollon Wealth Management LLC purchased a new stake in Tempus AI, Inc. (NASDAQ:TEM – Free Report) in the second quarter, according to its most recent filing with the SEC. The fund purchased 3,770 shares of the company’s stock, valued at approximately $240,000.
Several other large investors have also recently added to or reduced their stakes in the company. ARK Investment Management LLC boosted its holdings in Tempus AI by 35.9% in the first quarter. ARK Investment Management LLC now owns 7,501,399 shares of the company’s stock worth $361,867,000 after purchasing an additional 1,981,755 shares during the period. Vanguard Group Inc. raised its holdings in shares of Tempus AI by 6,247.5% during the first quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company’s stock worth $289,204,000 after purchasing an additional 5,900,668 shares during the period. Nikko Asset Management Americas Inc. lifted its position in shares of Tempus AI by 31.5% in the 1st quarter. Nikko Asset Management Americas Inc. now owns 4,260,553 shares of the company’s stock worth $205,401,000 after buying an additional 1,021,460 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Tempus AI by 31.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,255,477 shares of the company’s stock worth $205,284,000 after buying an additional 1,016,384 shares during the last quarter. Finally, CloudAlpha Capital Management Limited Hong Kong acquired a new position in shares of Tempus AI in the 1st quarter valued at about $34,119,000. 24.22% of the stock is currently owned by institutional investors.
Insider Activity
In other Tempus AI news, Director Theodore Leonsis sold 44,000 shares of the business’s stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $69.90, for a total transaction of $3,075,600.00. Following the sale, the director directly owned 86,756 shares in the company, valued at approximately $6,064,244.40. The trade was a 33.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James William Rogers sold 7,528 shares of the company’s stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total transaction of $561,965.20. Following the completion of the sale, the chief financial officer directly owned 138,473 shares of the company’s stock, valued at approximately $10,337,009.45. This represents a 5.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 933,662 shares of company stock worth $68,070,993 in the last 90 days. 26.27% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
Get Our Latest Report on Tempus AI
Tempus AI Price Performance
NASDAQ TEM opened at $87.78 on Friday. The company has a 50-day moving average price of $82.18 and a two-hundred day moving average price of $66.23. Tempus AI, Inc. has a 52 week low of $31.36 and a 52 week high of $104.32. The stock has a market cap of $15.25 billion, a price-to-earnings ratio of -73.76 and a beta of 4.87. The company has a current ratio of 1.54, a quick ratio of 1.43 and a debt-to-equity ratio of 2.58.
Tempus AI (NASDAQ:TEM – Get Free Report) last issued its quarterly earnings data on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. The business had revenue of $314.64 million during the quarter, compared to the consensus estimate of $296.84 million. Tempus AI had a negative return on equity of 122.86% and a negative net margin of 20.98%.The business’s revenue was up 89.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($6.86) earnings per share. Tempus AI has set its FY 2025 guidance at EPS. Analysts forecast that Tempus AI, Inc. will post -6.15 EPS for the current year.
Tempus AI Profile
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Recommended Stories
- Five stocks we like better than Tempus AI
- Buy P&G Now, Before It Sets A New All-Time High
- Johnson & Johnson’s M&A Strategy Is the Real Story for Investors
- How to Profit From Growth Investing
- Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?
- What is the Dogs of the Dow Strategy? Overview and Examples
- Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?
Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM – Free Report).
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.